Your browser doesn't support javascript.
loading
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.
Takada, Kazuki; Buti, Sebastiano; Bersanelli, Melissa; Shimokawa, Mototsugu; Takamori, Shinkichi; Matsubara, Taichi; Takenaka, Tomoyoshi; Okamoto, Tatsuro; Hamatake, Motoharu; Tsuchiya-Kawano, Yuko; Otsubo, Kohei; Nakanishi, Yoichi; Okamoto, Isamu; Pinato, David J; Cortellini, Alessio; Yoshizumi, Tomoharu.
Afiliação
  • Takada K; Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
  • Buti S; Department of Medicine and Surgery, University of Parma, Parma, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Shimokawa M; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Takamori S; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Matsubara T; Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Takenaka T; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Okamoto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Hamatake M; Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Tsuchiya-Kawano Y; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Otsubo K; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Nakanishi Y; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Okamoto I; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Pinato DJ; Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Translational Medicine, Università Del Piemonte Orientale "A. Avogadro", Novara, Italy.
  • Cortellini A; Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: a.cortellini@imperial.ac.uk.
  • Yoshizumi T; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eur J Cancer ; 172: 199-208, 2022 09.
Article em En | MEDLINE | ID: mdl-35780526
BACKGROUND: We previously validated in European patients with NSCLC treated with programmed death-1 (PD-1) checkpoint inhibitors the cumulative detrimental effect of concomitant medications. MATERIALS AND METHODS: We evaluated the prognostic ability of a "drug score" computed on the basis of baseline corticosteroids, proton pump inhibitors, and antibiotics, in an independent cohort of Japanese patients with advanced NSCLC treated with PD-1 monotherapy. Subsequently, we assessed the impact of baseline probiotics on the score's diagnostic ability and their interaction with antibiotics in influencing survival. RESULTS: Among the 293 eligible patients, good (19.5 months), intermediate (13.4 months), and poor (3.7 months) risk groups displayed a significantly different overall survival (OS) (log-rank test for trend: p = 0.016), but with a limited diagnostic ability (C-index: 0.57, 95%CI: 0.53-0.61), while no significant impact on progression-free survival (PFS) was reported (log-rank test for trend: p = 0.080; C-index: 0.55, 95%CI: 0.52-0.58). Considering the impact of the probiotics∗antibiotics interaction (p-value 0.0510) on OS, we implemented the drug score by assigning 0 points to concomitant antibiotics and probiotics. With the adapted drug score good, intermediate, and poor risk patients achieved a median OS of 19.6 months, 13.1 months, and 3.7 months, respectively, with a similar diagnostic ability (log-rank test for trend: p = 0.006; C-index: 0.58, 95%CI: 0.54-0.61). However, the diagnostic ability for PFS of the adapted score was improved (log-rank test for trend: p = 0.034; C-index: 0.62, 95%CI: 0.54-0.69). CONCLUSIONS: Although we failed to validate the drug score in this independent Japanese cohort, we showed that probiotics may have an antibiotic-dependent impact on its prognostic value. Further investigation looking at the effect of concomitant medications and probiotics across cohorts of different ethnicities is warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Probióticos / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Probióticos / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article